Science and Research

Development and characterization of anti-fibrotic natural compound similars with improved effectivity

Cardiac fibroblasts constitute the major cell type of the murine and human heart. Once activated, they contribute to an excessive deposition of extracellular matrix (ECM) leading to cardiac fibrosis and subsequently organ dysfunction. With the exception of the pulmonary drugs, nintedanib and pirfenidone, drugs specifically targeting anti-fibrotic pathways are scarce. We recently performed large library screenings of natural occurring compounds and identified first lead structures with anti-fibrotic properties in vitro and in vivo. In line, we now aimed to improve efficacy of these anti-fibrotic lead structures by combining in vitro validation studies and in silico prediction. Next to this combined approach, we performed large OMICs-multi-panel-based mechanistic studies. Applying human cardiac fibroblasts (HCF), we analysed 26 similars of the initially identified anti-fibrotic lead molecules bufalin and lycorine and determined anti-proliferative activity and potential toxicity in an array of in vitro and ex vivo studies. Of note, even at lower concentrations, certain similars were more effective at inhibiting HCF proliferation than nintedanib and pirfenidone. Additionally, selected similars showed low cytotoxicity on human iPS-derived cardiomyocytes and anti-fibrotic gene regulation in human ex vivo living myocardial slices. Further, array and RNA sequencing studies of coding and non-coding RNAs in treated HCFs revealed strong anti-fibrotic properties, especially with the lycorine similar lyco-s (also known as homoharringtonine), that led to a nearly complete shutdown of ECM production at concentrations 100-fold lower than the previously identified anti-fibrotic compound lycorine without inducing cellular toxicity. We thus identified a new natural compound similar with strong anti-fibrotic properties in human cardiac fibroblasts and human living heart tissue potentially opening new anti-fibrotic treatment strategies.

  • Kreutzer, F. P.
  • Meinecke, A.
  • Mitzka, S.
  • Hunkler, H. J.
  • Hobuß, L.
  • Abbas, N.
  • Geffers, R.
  • Weusthoff, J.
  • Xiao, K.
  • Jonigk, D. D.
  • Fiedler, J.
  • Thum, T.

Keywords

  • Bufalin
  • Cardiac fibroblast
  • Cardiac fibrosis
  • Heart failure
  • Homoharringtonine
  • Lycorine
  • Natural compounds
Publication details
DOI: 10.1007/s00395-022-00919-6
Journal: Basic Res Cardiol
Pages: 9 
Number: 1
Work Type: Original
Location: BREATH
Disease Area: General Lung and Other
Partner / Member: ITEM, MHH
Access-Number: 35235052

DZL Engagements

chevron-down